Lenvatinib

Generic Name
Lenvatinib
Brand Names
Lenvima 10, Kisplyx, Lenvima
Drug Type
Small Molecule
Chemical Formula
C21H19ClN4O4
CAS Number
417716-92-8
Unique Ingredient Identifier
EE083865G2
Background

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...

Indication

Lenvatinib is indicated for the treatment of the following cancerous conditions:

Differentiated Thyroid Cancer (DTC)

Renal Cell Carcinoma (RCC)

Hepatocellular Carcinoma (HCC)

Endometrial Carcinoma

Associated Conditions
Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
Associated Therapies
-
Clinical Trials
Related News

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

First Posted Date
2024-02-20
Last Posted Date
2024-03-13
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
30
Registration Number
NCT06266338
Locations
🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)

First Posted Date
2024-02-15
Last Posted Date
2024-03-12
Lead Sponsor
Mian XI
Target Recruit Count
60
Registration Number
NCT06261125
Locations
🇨🇳

Mian Xi, Guangzhou, Guangdong, China

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

First Posted Date
2024-02-12
Last Posted Date
2024-12-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT06253494
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma

First Posted Date
2024-02-12
Last Posted Date
2024-03-07
Lead Sponsor
First Affiliated Hospital Bengbu Medical College
Target Recruit Count
30
Registration Number
NCT06253598

HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)

Phase 2
Not yet recruiting
Conditions
Hepatocellular Carcinoma With PVTT
Interventions
Drug: Tislelizumab
Drug: Lenvatinib
First Posted Date
2024-01-18
Last Posted Date
2024-02-20
Lead Sponsor
Li Xiao Wei
Target Recruit Count
54
Registration Number
NCT06210334
Locations
🇨🇳

Eastern Hepatobiliary Surgery Hospital, Yangpu, Shanghai, China

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

First Posted Date
2024-01-17
Last Posted Date
2024-11-20
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
33
Registration Number
NCT06208462
Locations
🇨🇳

The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

First Posted Date
2024-01-11
Last Posted Date
2024-01-11
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
200
Registration Number
NCT06201065
Locations
🇨🇳

Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Neoplasms
Interventions
Drug: Erlotinib
Drug: Lenvatinib
Drug: Axitinib
First Posted Date
2023-12-08
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
70
Registration Number
NCT06161558
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

Phase 1
Not yet recruiting
Conditions
Breast Neoplasms
Interventions
Drug: Sindilimab
Drug: Nab-paclitaxel
Drug: Lenvatinib
First Posted Date
2023-11-20
Last Posted Date
2023-11-20
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
58
Registration Number
NCT06140576
Locations
🇨🇳

ZhejiangCH, Hangzhou, Zhejiang, China

Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma

Phase 2
Active, not recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Lenvatinib
First Posted Date
2023-11-18
Last Posted Date
2024-07-03
Lead Sponsor
Asan Medical Center
Target Recruit Count
50
Registration Number
NCT06138769
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy